{
    "ticker": "ALRN",
    "name": "Aileron Therapeutics, Inc.",
    "description": "Aileron Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for cancer and other serious diseases through its proprietary platform of stapled peptides. Founded in 2008, Aileron aims to transform the treatment landscape by harnessing the unique properties of stapled peptides, which are designed to stabilize the peptide structure and enhance its therapeutic potential. The company's lead product candidate, ALRN-6924, is being developed for the treatment of p53-related cancers, providing a novel approach to restoring the function of the p53 tumor suppressor protein. Aileron is committed to leveraging its platform to address unmet medical needs in oncology, with a vision of improving patient outcomes through precision medicine. The company collaborates with leading research institutions and pharmaceutical partners to advance its pipeline and explore new therapeutic applications. Aileron\u2019s innovative approach has garnered attention in the biotech community, positioning it as a promising player in the field of targeted cancer therapy.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "2008",
    "website": "https://www.aileronrx.com",
    "ceo": "Manuel Aivado",
    "social_media": {
        "twitter": "https://twitter.com/aileronrx",
        "linkedin": "https://www.linkedin.com/company/aileron-therapeutics/"
    },
    "investor_relations": "https://investors.aileronrx.com",
    "key_executives": [
        {
            "name": "Manuel Aivado",
            "position": "CEO"
        },
        {
            "name": "John E. Sweeney",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutic Candidates",
            "products": [
                "ALRN-6924"
            ]
        }
    ],
    "seo": {
        "meta_title": "Aileron Therapeutics, Inc. | Innovators in Stapled Peptide Technology",
        "meta_description": "Explore Aileron Therapeutics, Inc., a biotechnology company developing stapled peptide therapeutics for cancer treatment. Learn about our innovative approaches and pipeline.",
        "keywords": [
            "Aileron Therapeutics",
            "Stapled Peptides",
            "ALRN-6924",
            "Cancer Therapy",
            "Biotechnology",
            "Oncology"
        ]
    },
    "faq": [
        {
            "question": "What is Aileron Therapeutics known for?",
            "answer": "Aileron Therapeutics is known for developing stapled peptide therapeutics for cancer and other serious diseases."
        },
        {
            "question": "Who is the CEO of Aileron Therapeutics?",
            "answer": "Manuel Aivado is the CEO of Aileron Therapeutics, Inc."
        },
        {
            "question": "Where is Aileron Therapeutics headquartered?",
            "answer": "Aileron Therapeutics is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "What is Aileron's lead product candidate?",
            "answer": "Aileron's lead product candidate is ALRN-6924, aimed at treating p53-related cancers."
        },
        {
            "question": "When was Aileron Therapeutics founded?",
            "answer": "Aileron Therapeutics was founded in 2008."
        }
    ],
    "competitors": [
        "CLVS",
        "NVS",
        "BMY",
        "AMGN"
    ],
    "related_stocks": [
        "MRNA",
        "REGN",
        "GILD",
        "BIO"
    ]
}